---
title: "Descartes-08 in Generalized myasthenia gravis: Budget impact"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Budget impact. 1 evidence topic quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary/budget-impact"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Descartes-08

<a id="topic-1.1.3-1"></a>

### Summary

The report holds no budget impact model and no announced price for Descartes-08; the company states that it has no products approved for sale and has not generated any product sales. The inputs a model would draw on are quoted elsewhere in the report:

- Eligible population: ICER's 2021 budget impact analysis estimated 46,870 U.S. patients with gMG (MGFA clinical classification II to IV), assumed that 100% would be diagnosed, and assumed that 20% would initiate the new treatment in each of five years (9,374 additional patients per year). ICER states that approximately 80% of patients with generalized MG have AChR autoantibodies; a November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020, and AURORA is designed for participants with AChR antibody-positive MG. The company estimates that MG affects over 106,000 patients in the U.S., and a study of MarketScan databases estimated approximately 82,715 U.S. adults living with MG in 2021. Among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were classified as ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first and fifth treatment episodes.
- Dosing: AURORA administers Descartes-08 as six once-weekly infusions without preconditioning chemotherapy, and the company describes it as designed for outpatient administration. A company presentation cites projections “inclusive of opportunity to retreat patients”.
- Comparator costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart (2 or 3 vials per dose, weight based) as of September 30, 2025, $16,410.23 per vial and $17,066.64 per syringe of Vyvgart Hytrulo (1 per dose) as of October 1, 2026, and $140,248.50 per dose of Uplizna (2025); a price of $6,523 per single-dose vial of Soliris (2025). One study estimated the annual cost of health-care-provider-administered gMG treatment at $223,272 to $648,960 depending on drug and body weight.
- Cell therapy costs: among 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma, the median cost of CAR-T products was $402 500 and median total costs $608 100. Across 391 Medicare CAR-T claims, the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. CMS pays an inpatient CAR-T case through a single DRG payment for the stay and a solely outpatient case at Average Sales Price plus 6%; in the FY 2027 final rule, CMS estimated average costs of $410,125 for nonclinical trial cases assigned to MS-DRG 018. Costs of cilta-cel therapy excluding product acquisition were estimated at US$160,933 over 12 months, including $18,268 in pre-infusion costs such as apheresis.
- Budget thresholds in prior ICER assessments: 8.8% of the eligible gMG population could be treated with efgartigimod at its placeholder price without passing ICER's budget impact threshold, and 43% of eligible multiple myeloma patients could be treated with ide-cel at its list price of $419,500 within five years before crossing the threshold of $819 million per year.

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm); [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456); [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/); [Harris et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447171/); [Grover et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42839213/); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_WAC_Disclosure_for_Colorado_HCPs.pdf); [argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_Hytrulo_WAC_Disclosure_for_Colorado_HCPs.pdf); [Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025)](https://www.managedhealthcareexecutive.com/view/fda-approves-uplizna-for-chronic-inflammatory-condition-igg4-rd); [Managed Healthcare Executive eculizumab biosimilars article (2025)](https://www.managedhealthcareexecutive.com/view/bkemv-and-epysqli-two-biosimilars-of-soliris-are-now-available); [Tse et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41422493/); [Di et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/); [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11263250/); [Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026)](https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and); [Jagannath et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10260711/); [ICER multiple myeloma final evidence report (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Unredacted_112222.pdf)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
